Metabolic & Endocrine
Diabetes
3
Pipeline Programs↗
38
Active Trials↗
22
Companies Involved↗
Diabetes is an early-stage landscape with 3 programs across 22 companies. The most active players are Chiesi Farmaceutici S.p.A., Eli Lilly, Novo Nordisk. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 3
No programs
Approved1
Analysis
Trial Status
174
clinical trials
Completed108 · 62%
Recruiting17 · 10%
Unknown status16 · 9%
Not yet recruiting15 · 9%
Withdrawn6 · 3%
Active, not recruiting6 · 3%
Other6 · 3%
Clinical Trials
Trial Activity
174 trials
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT06108076·10 enrolled
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Recruiting·—·N/A·NCT05008276·100 enrolled
Doxycycline in Type II Diabetes
Recruiting·—·Phase 1/2·NCT06329882·60 enrolled
Urinary Vitamin C Loss in Subjects With and Without Diabetes
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT00071526·5,000 enrolled
Personalized Environment and Genes Study
Recruiting·National Institute of Environmental Health Sciences (NIEHS)·N/A·NCT00341237·25,000 enrolled
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)